Follow The Filings

BSX Boston Scientific

Health Care, filed as BOSTON SCIENTIFIC CORP (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 6 managers in 2026 Q2, sold by 3

  • 1 Owner
  • #104
  • Max 0.4%
  • Master 0.04%
  • $1.1M
  • 1 new

In 2026 Q3 Murphy Pohlad opened a position in Boston Scientific.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Murphy Pohlad, Murphy Pohlad Asset Management). Not free-float ownership.

  1. Murphy Pohlad New 0.38%

Who owns BSX

Sorted by value, long equity only, as of 2026 Q3.

History
Murphy Pohlad, Murphy Pohlad Asset Management 0.38% New 0.38% 25,210 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BSX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BSX insider trades
  • $10M bought by 5 insiders
  • None no sales outside a trading plan
  • $23M sold by 4 insiders under 10b5-1 plans
  1. Susan E Morano Director
    Buy
    $100K 2,040 shares at $49.22 +17% to stake
    Traded Aug 25 Filed Aug 26
    ↗
  2. David C Habiger Director
    Buy
    $100K 2,100 shares at $47.59 +14% to stake
    Traded Aug 5 Filed Aug 7
    ↗
  3. David C Habiger Director
    Buy
    $57K 1,182 shares at $48.13 +8.5% to stake
    Traded Aug 3–4 Filed Aug 5
    ↗
  4. Michael F Mahoney CEO
    Buy
    $9M 186,240 shares at $48.33 +13% to stake
    Traded Aug 3 Filed Aug 5
    ↗
  5. Edward J Ludwig Director
    Buy
    $227K 5,000 shares at $45.48 +20% to stake
    Traded Jul 31 Filed Aug 3
    ↗
  6. Cheryl Pegus Director
    Buy
    $100K 1,770 shares at $56.49 New stake
    Traded May 20 Filed May 21
    ↗
  7. Edward J Ludwig Director
    Buy
    $203K 3,580 shares at $56.68 +16% to stake
    Traded May 20 Filed May 21
    ↗
  8. David C Habiger Director
    Buy
    $251K 4,450 shares at $56.43 +47% to stake
    Traded May 19–20 Filed May 21
    ↗
  9. Michael F Mahoney CEO
    Planned sale
    $15M 160,901 shares at $93.49 10% of stake
    Traded Feb 2 Filed Feb 3
    ↗
  10. Arthur C Butcher EVP& Grp Pres, MedSurg & APAC
    Planned sale
    $1.8M 17,313 shares at $101.55 42% of stake
    Traded Dec 1, 2025 Filed Dec 2, 2025
    ↗
  11. Ellen M Zane Director
    Planned sale
    $1.3M 12,891 shares at $98.28 35% of stake
    Traded Nov 6, 2025 Filed Nov 6, 2025
    ↗
  12. Joseph Michael Fitzgerald EVP & Group Pres, Cardiology
    Planned sale
    $5M 50,000 shares at $99.47 22% of stake
    Traded Nov 3, 2025 Filed Nov 4, 2025
    ↗
  13. Ellen M Zane Director
    Planned sale
    $1.3M 12,891 shares at $101.38 35% of stake
    Traded Oct 27–28 Filed Oct 28, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 44 option exercises, 37 share withholdings for taxes, 20 stock grants, 5 gifts, and 5 other transactions.

Congress

10 members of Congress traded BSX in the last three years: 16 buys and 25 sales. 11 members listed it in 2025 annual reports.

All Congress trades
  1. Kevin Hern R-OK-1Joint Sell $50K–$100K Sep 9 filed Sep 25
  2. Kevin Hern R-OK-1Joint Partial sale $50K–$100K Sep 4 filed Sep 25
  3. Kevin Hern R-OK-1Child Sell $1K–$15K Sep 3 filed Sep 25
  4. Kevin Hern R-OK-1Child Sell $1K–$15K Sep 3 filed Sep 25
  5. Kevin Hern R-OK-1Child Sell $1K–$15K Sep 3 filed Sep 25
  6. Kevin Hern R-OK-1Joint Sell $15K–$50K Aug 31 filed Sep 25

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
8-K 5.02,8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 1.05 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.05 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $14.24B $16.75B $20.07B
Gross profit $9.9B $11.49B $13.85B
Gross margin * 69.5% 68.6% 69.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $6.51B $6.92B $8.79B
Total non-current assets * $28.62B $32.48B $34.88B
Total assets $35.14B $39.4B $43.67B
Total current liabilities $4.93B $6.4B $5.44B
Total equity $19.28B $21.77B $24.23B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $2.5B $3.44B $4.53B
Cash from investing -$2.57B -$5.69B -$2.64B
Cash from financing $0.005B $1.81B -$0.395B
Net change in cash -$0.07B -$0.45B $1.54B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.